US 2026/0108571 A1Published application

Mycobacteriophage compositions and related methods

AssigneeOregon State University

InventorLia Danelishvili

Life of this patent

Estimating the term…

Loading patent…

Abstract

Disclosed are isolated bacteriophages having lytic activity against a broad range of mycobacterial species, as well as phage cocktails comprising different mixtures of the isolated bacteriophages. The disclosed bacteriophages include Pill582, and variants thereof, having the ability to stimulate TLR2 signaling and limit intracellular bacterial survival within macrophages through the signalosome involving NLRP3 inflammasome activation leading to the caspase 1 activation and the production of pro-inflammatory cytokine IL-1β. Also disclosed are compositions comprising the isolated bacteriophages or phage cocktails, including pharmaceutical compositions and compositions further comprising one or more non-phage therapeutic agents. The disclosed bacteriophage and phage cocktail compositions are useful in methods for treating mycobacterial infections and associated disease conditions.

Claims29

Dependent claims

A phage cocktail comprising at least two bacteriophages selected from the group consisting of:

a first isolated bacteriophage having a genome that has at least 95% sequence identity with the genome of bacteriophage Pill582, deposited under ATCC Patent Deposit Designation No. PTA-127809, wherein said first isolated bacteriophage (a) has lytic activity against Mycobacterium abscessus, Mycobacterium avium subspecies hominissuis, and Mycobacterium fortuitum, and (b) stimulates TLR2 signaling in THP-1 human macrophages;
a second isolated bacteriophage having a genome that has at least 95% sequence identity with the genome of bacteriophage Ore278, deposited under ATCC Patent Deposit Designation No. PTA-127810, wherein said second isolated bacteriophage has lytic activity against Mycobacterium avium subspecies paratuberculosis, Mycobacterium abscessus, Mycobacterium avium subspecies hominissuis, Mycobacterium fortuitum, Mycobacterium bovis BCG, Mycobacterium tuberculosis, Mycobacterium kansasii, and Mycobacterium gordonae;
and
a third isolated bacteriophage having a genome that has at least 95% sequence identity with the genome of bacteriophage Minn381, deposited under ATCC Patent Deposit Designation No. PTA-127811, wherein said third isolated bacteriophage has lytic activity against Mycobacterium avium subspecies paratuberculosis, Mycobacterium abscessus, Mycobacterium avium subspecies hominissuis, Mycobacterium fortuitum, Mycobacterium bovis BCG, Mycobacterium tuberculosis, Mycobacterium kansasii, and Mycobacterium gordonae.

1 more element

Dependencies are inferred from the claim text.